Back to search results
NCT07216040

Harnessing Optimism and Perseverance in the Face of Long COVID-Español

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Icahn School of Medicine at Mount Sinai
~25 participants
Updated 2026-04-23 on ClinicalTrials.gov
What's tested:HOPE-LC~Espanol

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recruitment rate
Measured over Throughout the study period, 12 weeks
+4 more outcomes measured

Conditions

Post-Acute COVID-19 Syndrome

NCT07216040

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Brain Injury Research Center

    New York, New Yorkstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Eric Watson · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine
  • Amelia Hicks, PhD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine

Who to contact

Eric Watson, PhD
[email protected]
212-241-2221
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older.
Speaks and understands Spanish at a level that allows active participation in group-based study procedures.
Self-reported history of Long COVID/post-COVID condition of any severity or duration, including ongoing emotional or cognitive symptoms affecting daily functioning or a medical professional has diagnosed you with a Long COVID/post-COVID condition of any severity or duration, including ongoing emotional or cognitive symptoms.
Ability to participate in group sessions either in-person or via telehealth (Zoom).
Willingness and capacity to provide informed consent.

Exclusion

Presence of severe psychiatric conditions that would preclude participation in group therapy (e.g., active psychosis, suicidal intent requiring immediate intervention).
Inability to communicate in Spanish sufficiently to engage meaningfully in group sessions.
Cognitive or physical impairments prevent participation in group sessions or completion of surveys, without available accommodations.
Concurrent participation in another conflicting interventional trial targeting Long COVID symptoms.

What this trial measures

  • Recruitment rateThroughout the study period, 12 weeks

    Number of eligible participants screened and enrolled by referral source

  • Retention rateThroughout the study period, 12 weeks

    Number of participants completing the intervention (defined as attending at least 8 of 12 sessions)

  • Number of sessions participants attendedThroughout the study period, 12 weeks

    Feasibility measured via participant attendance

  • Number of completed surveysThroughout the study period, 12 weeks

    Feasibility measured via number of surveys completed from participant follow-up and study procedures.

  • Patient SatisfactionPost-treatment (Week 12)

    Post-treatment survey assessing participant satisfaction with HOPE-LC\~Español. Items are on a 5-point Likert Scale evaluated agreement to statements about their experience in the program (e.g., feeling heard, learning practical strategies, and willingness to recommend the program). The total score range is 5 - 40, with higher ratings indicating greater satisfaction.